Information Provided By:
Fly News Breaks for January 31, 2017
NVS, TEVA, MNTA
Jan 31, 2017 | 08:08 EDT
Leerink analyst Jason Gerberry says the pro-generic ruling by the federal district court in Teva's (TEVA) Copaxone patent case further reduces the barriers to a Momenta (MNTA)/Novartis (NVS) generic launch in 2017. The analyst now assigns a higher likelihood to a Momenta this year, with a 90% probability. Moreover, Gerberry believes that among the five litigants in the Copaxone 40mg litigation, Momenta is "best positioned" to secure generic approval as it was the only entity to demonstrate bioequivalence to Copaxone's active ingredient. He reiterated an Outperform rating on Momenta's stock, and raised his price target on the shares to $20 from $19.
News For MNTA;TEVA;NVS From the Last 2 Days
There are no results for your query MNTA;TEVA;NVS